Product Description: ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is a glycosphingolipid (GSL) biosynthetic enzyme that can inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 can be used in cancer research[1].
Formula: N/A
References: [1]Zhang J, et al. ST3GAL5-catalyzed gangliosides inhibit TGF-β-induced epithelial-mesenchymal transition via TβRI degradation. EMBO J. 2023 Jan 16;42(2):e110553.
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: TGF-beta/Smad